lurasidone cas367514-87-2 99% best service hot sale
ISO TDS
367514-87-2
Pharmaceutical Grade
99.6%
us
Million
25kg/Cardboard Drum
2100-12-31
Avanafil,Tirzepatide,Semaglutide,Pregabalin,Nootropics,MT2
-
Product Description
-
Seller Information
-
DescriptionECHEMI Editorial ReferenceLurasidone is an antagonist of both dopamine D2 and 5-HT7 with IC50s of 1.68 and 0.495 nM, respectively. Lurasidone is also a partial agonist of 5-HT1A receptor with an IC50 of 6.75 nM.
Lurasidone is an N-arylpiperazine that is (3aR,4S,7R,7aS)-2-{[(1R,2R)-2-(piperazin-1-ylmethyl)cyclohexyl]methyl}hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione in which position N4 of the piperazine ring is substituted by a 1,2-benzothiazol-3-yl group. Lurasidone is used (generally as the hydrochloride salt) as an atypical antipsychotic for the treatment of schizophrenia. It has a role as an adrenergic antagonist, a dopaminergic antagonist, a serotonergic antagonist and a second generation antipsychotic. It is a 1,2-benzisothiazole, a N-arylpiperazine, a bridged compound and a dicarboximide. It derives from a maleimide. It is a conjugate base of a lurasidone(1+).|Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.|Lurasidone is an Atypical Antipsychotic.|Lurasidone is a second generation (atypical) antipsychotic agent that is used in the treatment of schizophrenia and bipolar depression. Lurasidone is associated with a low rate of serum aminotransferase elevations during therapy, but has not been linked to instances of clinically apparent acute liver injury.|A thiazole derivative and atypical ANTIPSYCHOTIC AGENT that functions as a DOPAMINE D2 RECEPTOR ANTAGONIST; SEROTONIN 5-HT2 RECEPTOR ANTAGONIST, serotonin 5-HT7 receptor antagonist, and antagonist of the adrenergic α2A and α2C receptors, as well as a partial SEROTONIN 5-HT1A RECEPTOR AGONIST. It is used in the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER.CertificatesBasic Info-
Product Name:
Lurasidone
Other Name:4,7-Methano-1H-isoindole-1,3(2H)-dione,2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-,(3aR,4S,7R,7aS)-;(3aR,4S,7R,7aS)-2-[[(1R,2R)-2-[[4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione;Lurasidone;2-[[(1R,2R)-2-[[4-(1,2-Benzoisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-(3aS,4R,7S,7aR)-4,7-methano-1H-isoindole-1,3(2H)-dione
CAS No.:367514-87-2
Molecular Formula:C28H36N4O2S
InChIKeys:InChIKey=PQXKDMSYBGKCJA-CVTJIBDQSA-N
Molecular Weight:492.67604
Exact Mass:492.68
EC Number:1308068-626-2
UNII:22IC88528T
ATC Code:N05AE05|N - Nervous system
Categories:
Characteristics-
PSA:
85
XLogP3:4.89 (est)
Density:1.273
Boiling Point:623.4±55.0 °C at 760 mmHg
Flash Point:9.7 deg C (49.5 deg F) - closed cup
Refractive Index:1.637
Water Solubility:In water, 5.32X10-2 mg/L at 25 deg C (est)
Storage Conditions:Conditions for safe storage, including any incompatibilities: Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully resealed and kept upright to prevent leakage. Recommended storage temperature -20 deg C
Vapor Pressure:1.33X10-16 mm Hg at 25 deg C (est)
Henrys Law Constant:Henry's Law constant = 3.74 atm-cu m/mol at 25 °C (est)
Dissociation Constants:pKa1 = 1.96 (imine); pKa2 = 8.50 (amine) (est)
Experimental Properties:White to off-white powder; MP 215-217 °C; sparingly soluble in methanol; slightly soluble in ethanol; very slightly soluble in acetone, water; practically insoluble in 0.1 N HCl, toluene /Lurasidone hydrochloride/|Hydroxyl radical reaction rate constant = 3.69X10-10 cu cm/molec-sec at 25 °C (est)
Hazard IdentificationClassification of the substance or mixture
Specific target organ toxicity â single exposure, Category 3
Carcinogenicity, Category 2
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Warning
Hazard statement(s) H336 May cause drowsiness or dizziness
H351 Suspected of causing cancer
Precautionary statement(s) Prevention P261 Avoid breathing dust/fume/gas/mist/vapours/spray.
P271 Use only outdoors or in a well-ventilated area.
P203 Obtain, read and follow all safety instructions before use.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
Response P304+P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.
P319 Get medical help if you feel unwell.
P318 IF exposed or concerned, get medical advice.
Storage P403+P233 Store in a well-ventilated place. Keep container tightly closed.
P405 Store locked up.
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Avanafil,Tirzepatide,Semaglutide,Pregabalin,Nootropics,MT2
-
Location:
Room 1-2208, Lianhecaifu Square, No2177, Tianchen Road, Gaoxin District, Jinan City, Shandong Province, China
-
Payment Terms:
L/C,100% TT in advance
-
Average lead Time:
3
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2012
-
Certifications:
business license
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
